Esperion Therapeutics Reports Strong 2025 Revenue Growth, Reduced Loss, Confirms Corstasis Acquisition, But Faces Material Weakness in Internal Controls
Summary
Esperion Therapeutics reported strong 2025 financial results with increased revenue and a significantly reduced net loss, while confirming a strategic acquisition, but the report also disclosed a material weakness in internal controls and an adverse auditor opinion on their effectiveness.
Key Events
-
Material Weakness in Internal Controls Identified
Management concluded that internal control over financial reporting was not effective as of December 31, 2025, due to a material weakness related to the accounting for inventory held at a third-party contract manufacturing organization. This issue was previously reported in Q2 2025.
-
Auditor Issues Adverse Opinion on Internal Controls
Ernst & Young LLP issued an adverse opinion on the effectiveness of Esperion Therapeutics' internal control over financial reporting for the year ended December 31, 2025, reinforcing the severity of the identified material weakness.
-
Significant Reduction in Annual Net Loss
The company reported a net loss of $22.7 million for the year ended December 31, 2025, a substantial improvement from a net loss of $51.7 million in 2024 and $209.2 million in 2023.
-
Strong Revenue Growth in 2025
Total revenues increased to $403.1 million in 2025 from $332.3 million in 2024, driven by a rise in net product sales to $159.6 million and collaboration revenue of $243.6 million, including a $90 million milestone payment from Otsuka.
Analysis
This annual report provides a comprehensive overview of Esperion Therapeutics' 2025 performance, revealing significant revenue growth and a substantial reduction in net loss, indicating a positive operational trajectory. The company also confirmed its strategic acquisition of Corstasis Therapeutics, which is expected to diversify its product pipeline. However, a critical negative is the disclosed material weakness in internal control over financial reporting, further underscored by an adverse opinion from its independent auditor. This deficiency, related to inventory accounting, raises significant concerns about the reliability of financial reporting processes and corporate governance, despite the auditor issuing an unqualified opinion on the financial statements themselves. Investors should weigh the strong operational and strategic advancements against the serious internal control issues and ongoing ANDA litigation, which could impact future financial stability and investor confidence.
At the time of this filing, ESPR was trading at $2.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $645.5M. The 52-week trading range was $0.69 to $4.18. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.